A phase II/III trial of Primary radiothErapy for Androgen sensitive pRostate cancer patients with Lymph nodeS
Disease site: Prostate cancer, Urological cancers.
Treatment modality: Radiotherapy
Status: Open to recruitment
Trial details
PEARLS is a phase II/III, multicentre, randomised controlled trial for primary radiotherapy in androgen sensitive prostate cancer with positive lymph nodes. Phase II will determine whether moderately fractionated extended field intensity modulated radiotherapy (IMRT) is safe in node positive prostate cancer. Phase III will determine whether extended field IMRT improves metastasis-free survival (MFS) compared to standard field IMRT in patients with lymph node positive disease.
893 patients (150 phase II, 743 phase III) will be recruited from sites over a 6.5 year period. Patients will have daily radiotherapy treatment for 4 weeks and will be followed up after treatment for at least 5 years.
Further information
Chief Investigator: Dr Julia Murray, The Royal Marsden NHS Trust
ICR-CTSU Scientific Lead: Professor Emma Hall
Trial management contact: [email protected]
ISRCTN: https://www.isrctn.com/ISRCTN36344989
Sponsor: ICR
Funding: CRUK (A29872)
View PEARLS on the National Institute for Health Research website: NIHR - Be Part Of Research.
A lay summary in plain English is available from Cancer Research UK.
Note: If any links in this document are unavailable at the time of submission please log a new request to add them as soon as they become available.
Further information for potential participants